Hyaluronidase
- Generic Name
- Hyaluronidase
- Brand Names
- Amphadase
- Drug Type
- Biotech
- CAS Number
- 9001-54-1
- Unique Ingredient Identifier
- 8KOG53Z5EM
- Background
Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.
Hyaluronidase was first used in prescription products in the United States on 5 May 2004.
- Indication
Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.
- Associated Therapies
- Parenteral rehydration therapy, Parenteral drug administration, Subcutaneous urography
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT02519452
Hyaluronidase Effect on Infusion Set Life
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT02199028
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid's Surgery
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Duke University
- Registration Number
- NCT02059694
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
- Conditions
- Type 1 Diabetes
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 13
- Registration Number
- NCT01945099
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Reducing and Removing Hyaluronic Acid Filler with Hyaluronidase
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 5
- Registration Number
- NCT01722916
- Locations
- 🇺🇸
Northwestern University Department of Dermatology, Chicago, Illinois, United States
Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics
- Conditions
- Cardiac Arrhythmias
- Interventions
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Mauricio Jose Tornelli
- Target Recruit Count
- 20
- Registration Number
- NCT01719978
- Locations
- 🇧🇷
Stomatology Department, FOUSP, Sao Paulo, Brazil
Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
- Conditions
- Allergic Skin Reaction
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 253
- Registration Number
- NCT01689363
- Locations
- 🇺🇸
Amphastar Site 0026, Portland, Oregon, United States
🇺🇸Amphastar Site 0038, Renton, Washington, United States
🇺🇸Amphastar Site 0022, Eugene, Oregon, United States
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT01526733
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT01275131
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT01194258
- Locations
- 🇺🇸
Mercury Street Medical, Butte, Montana, United States
🇺🇸UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸John Muir Physician Network Clinical Research Center, Concord, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.